Dayli Partners
VC Fund
Seoul, South Korea
Dayli Partners is an investment firm.
- Total investments:
- 114
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Dayli Partners invests in
Stages Dayli Partners invests in
Countries Dayli Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $791k–$6.7M
- Series A
- $839k–$17M
- Series B
- $1.5M–$29M
Investment Focus
Industry
- Biotechnology 54 (47%)
- Health Care 41 (36%)
- Medical 34 (30%)
- Pharmaceutical 24 (21%)
- Therapeutics 16 (14%)
Stage
- Series A 29 (25%)
- Series B 25 (22%)
- Seed 16 (14%)
- Series C 11 (10%)
- Funding Round 11 (10%)
Country
- South Korea 86 (75%)
- United States 2 (2%)
- Indonesia 1 (1%)
- Singapore 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Seungho Lee
CEO
|
CEO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SN BioScience
|
SN BioScience provide nano-formulation screening services for small molecule, oligonucleotide (siRNA, DNA), peptide and protein to deliver in the form of nano-micelle, nanoparticle or liposome. Their proprietary “double core-shell technology” and pool of acceptable lipids and polymers could help your research that having difficulties in solubilityor delivery. | $9.3M / Venture - Series Unknown / Apr 07, 2026 | |
G2GBIO
|
G2GBIO operates to supply good medicines to patients all over the world and practice. | $52.5M / Post-IPO Debt / Feb 25, 2026 | |
Galux
|
Galux provides molecular design technology focusing on discovering and developing novel drugs for incurable and rare diseases using its AI-based drug design platform technologies. | $29M / Series B / Feb 09, 2026 | |
1st Biotherapeutics
|
1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success. 1STBIO currently has 24 employees with expertise in biochemistry, medicinal chemistry,pharmacology, and business development. We are working as a core expertise team of drug discovery/development and are rigorously connected to R&D networking of academia, hospitals, industry, CRO’s and investors in Korea, China and US. Our ultimate goal is to use our experience and knowledge to discover and develop effective molecular therapeutics for patients. | $21.9M / Series D / Jan 26, 2026 | |
Orum Therapeutics
|
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M / Post-IPO Equity / Dec 18, 2025 | |
Infoyou Financial Services
|
Infoyou Financial Services is an independent insurance agency that delivers financial consulting services in addition to sales and customer support. Its service portfolio includes the sale of insurance products, policy servicing, and personalized financial advisory solutions. | $13.6M / Series A / Nov 29, 2025 | |
Doctornow
|
Doctornow is a leading digital healthcare platform in South Korea and the pioneer of the nation's first remote medical consultations & drug delivery services. Doctornow offers a range of services, including medical AI assessments and real-time consultations with medical practitioners. | Series B / Sep 01, 2025 | |
Illimis Therapeutics
|
Illimis Therapeutics is a platform-based biotech company that develops a chimeric fusion protein platform for neurodegenerative diseases. The company's proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved inregulating inflammation and immune responses. | $41.9M / Series B / Jul 14, 2025 | |
Beamworks
|
Beamworks is a research-centered company in medical imaging and conversational AI, that enables expert-level cancer diagnosis anywhere in the world and providing reliable medical consultations at any time. The company's platform utilizes an on-device AI system that processes ultrasound data in real-time without the need for serverconnectivity, achieving detection sensitivity and differential diagnosis performance, enabling healthcare providers to offer precise and timely diagnostics and improve patient outcomes, and reduce unnecessary procedures. | $10.9M / Venture - Series Unknown / Jun 02, 2025 | |
CURAUM
|
CURAUM is a specialist in oral care and sleep-related health care products. | $14.6M / Series C / May 25, 2025 | |
| See all 114 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Dayli Partners invest in?
Dayli Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 114 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Dayli Partners's check size?
Dayli Partners typically joins rounds of $791k–$6.7M at Seed, $839k–$17M at Series A and $1.5M–$29M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Dayli Partners participates in.
How do I contact Dayli Partners?
Public channels for Dayli Partners include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dayli Partners?
The team at Dayli Partners includes Seungho Lee (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
